---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-090045"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2026-08-04T10:47:58+00:00"
generated_at: "2026-08-04T10:50:14.042796+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck Q2 2026: GAAP loss $0.54 on $16.6B sales; raises FY2026 guidance

## Summary
- Total worldwide sales $16.6B, up 5% (4% ex-FX); KEYTRUDA/KEYTRUDA QLEX sales $8.4B (+5%).
- GAAP loss per share $0.54; non-GAAP loss per share $0.13; both include $2.31/share charge for Terns acquisition.
- Full-year 2026 guidance: sales range raised to $66.3B-$67.3B; non-GAAP EPS $2.66-$2.76 (includes $2.43/share Terns charge).
- FDA approved LIPFENDRA (enlicitide), first once-daily oral PCSK9 inhibitor for hypercholesterolemia.
- Completed acquisition of Terns for $6.8B; added MK-4208 (BCR::ABL1 inhibitor) to pipeline.

## SEC filing metadata
- accession: 0001104659-26-090045
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2026-08-04T10:47:58+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/0001104659-26-090045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-090045
- JSON: https://secwatch.observer/filing/0001104659-26-090045.json
- Plain text: https://secwatch.observer/filing/0001104659-26-090045.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.